| Name | Title | Contact Details |
|---|
Northeast Precast is a state-of-the-art facility located in Vineland, NJ. It is our mission to become the preferred supplier in the Mid-Atlantic precast concrete market by providing operational excellence and superior customer service. Northeast Precast Advantage •(2) 50,000 sq ft Heated Indoor Casting Facilities •(16) Overhead Cranes (Up to 40 Ton Capacity) •(3) Gantry cranes (Up to 70 Ton Capacity) •30,000 sq ft Indoor Fabrication Shop •High Definition Plasma Cutter •Forms & Custom Trailers are Made In-house •(2) Concrete Batch Plants •Designated In-house Fleet of Tractors & Trailers
The International Center of Photography (ICP) is a prominent institution focused on photography and visual culture, founded in 1974 by photojournalist Cornell Capa. Located in New York Citys Lower East Side, ICP serves as a center for exhibitions, education, and public engagement, highlighting the significance of photography in contemporary society. ICP promotes "concerned photography," which emphasizes socially and politically driven imagery aimed at fostering global change. The center curates rotating exhibitions that showcase both historical and contemporary works, drawing from its extensive archives. It also offers educational programs, serving over 3,000 students annually through various courses and workshops in photography, filmmaking, and visual storytelling. Additionally, ICP engages the public through lectures, symposia, and community events that explore the societal role of photography. ICP targets students, artists, educators, and photography enthusiasts, providing tailored programs for aspiring professionals and lifelong learners. Its mission is to advance photography as a tool for social change and cultural dialogue, solidifying its position as a leader in visual arts education and exhibition.
Capital Bank N.A., headquartered in Rockville, Maryland is a Maryland chartered commercial bank that offers commercial and consumer banking services to clients in the Washington D.C. metropolitan area, alongside two nation-wide lending brands; Capital Bank Home Loans, a mortgage division that lends in all 50 states, and OpenSky a credit card division that offers and services credit cards across all states. Capital Bank focuses on merging digitally based products with personalized services. This enables our commercial sales teams, mortgage loan officers and OpenSky customer care associates to deliver a meaningful customer experience customized by the nature of the relationship, whether it be a credit card, a home loan, or a commercial customer with complicated lending and treasury needs. Our expansion has been deliberate with a focus on trading brick and mortar expenses for investment in digital technologies to enable our customers to focus on their goals, or their personal vision. For more information, visit https://capitalbankmd.com Member FDIC. An Equal Housing Lender. NMLS# 401599. CAPITAL BANK, PARTNERS IN YOUR VISION
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.